Clinical trials and new therapies in Sjögren's disease.

Area of Science:

• Rheumatology and Immunology
• Autoimmune Diseases
• Clinical Therapeutics

Background:

• Sjögren's disease (SjD) lacks approved disease-modifying therapies, necessitating symptomatic management.
• Current treatments often involve off-label immunomodulators, highlighting a significant unmet need for targeted SjD therapies.
• The therapeutic landscape for SjD is evolving with promising clinical trial results.

Purpose of the Study:

• To review the current state of therapeutic development for Sjögren's disease.
• To highlight recent advancements in clinical trials for SjD, including phase 2 and phase 3 studies.
• To discuss the impact of improved trial designs on evaluating novel SjD treatments.

Main Methods:

• Review of recent phase 2 and phase 3 clinical trial data for Sjögren's disease therapies.
• Analysis of efficacy signals from trials investigating ianalumab and telitacicept.
• Examination of evolving clinical trial design principles in SjD research.

Main Results:

• Phase 2 trials demonstrated meaningful efficacy signals for novel SjD treatments.
• Phase 3 trials of ianalumab and telitacicept showed positive outcomes, particularly in reducing systemic disease activity (EULAR Sjögren's Syndrome Disease Activity Index).
• Refined trial designs, including patient selection and endpoint development, are crucial for success.

Conclusions:

• Sjögren's disease may be entering an era of effective, disease-modifying therapies.
• Recent clinical trial successes indicate a maturing therapeutic pipeline for SjD.
• Optimized trial methodologies are essential for accurately assessing treatment efficacy in SjD.